Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) is a clinical-stage synthetic biology company focused on developing gene circuit-engineered cell and gene therapies, primarily targeting oncology indications. The company completed its business combination with Dynamics Special Purpose Corp (DYNS), a SPAC that priced its initial public offering in 2021, with the merger closing in June 2022. On September 2, 2026, Senti filed a Form DEFA14A — definitive additional proxy soliciting materials — with the SEC under accession number 0001628280-26-060129, indicating an active shareholder vote process is underway. The company operates in the biotechnology and cell therapy sector. Visit SpacDesk and sign up for full data, filings, and deal analytics on SNTI and hundreds of other SPAC-origin companies.